1. Home
  2. VYNE vs SST Comparison

VYNE vs SST Comparison

Compare VYNE & SST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VYNE
  • SST
  • Stock Information
  • Founded
  • VYNE 2003
  • SST 2013
  • Country
  • VYNE United States
  • SST United States
  • Employees
  • VYNE N/A
  • SST N/A
  • Industry
  • VYNE Biotechnology: Pharmaceutical Preparations
  • SST Diversified Commercial Services
  • Sector
  • VYNE Health Care
  • SST Consumer Discretionary
  • Exchange
  • VYNE Nasdaq
  • SST Nasdaq
  • Market Cap
  • VYNE 24.3M
  • SST 23.3M
  • IPO Year
  • VYNE 2018
  • SST N/A
  • Fundamental
  • Price
  • VYNE $0.35
  • SST $5.79
  • Analyst Decision
  • VYNE Buy
  • SST Strong Buy
  • Analyst Count
  • VYNE 2
  • SST 1
  • Target Price
  • VYNE $8.00
  • SST $10.00
  • AVG Volume (30 Days)
  • VYNE 4.1M
  • SST 50.3K
  • Earning Date
  • VYNE 08-14-2025
  • SST 08-07-2025
  • Dividend Yield
  • VYNE N/A
  • SST N/A
  • EPS Growth
  • VYNE N/A
  • SST N/A
  • EPS
  • VYNE N/A
  • SST N/A
  • Revenue
  • VYNE $476,000.00
  • SST $317,055,000.00
  • Revenue This Year
  • VYNE $42.51
  • SST N/A
  • Revenue Next Year
  • VYNE N/A
  • SST $8.39
  • P/E Ratio
  • VYNE N/A
  • SST N/A
  • Revenue Growth
  • VYNE N/A
  • SST N/A
  • 52 Week Low
  • VYNE $0.33
  • SST $2.90
  • 52 Week High
  • VYNE $4.30
  • SST $15.30
  • Technical
  • Relative Strength Index (RSI)
  • VYNE 29.46
  • SST 46.77
  • Support Level
  • VYNE $0.35
  • SST $4.95
  • Resistance Level
  • VYNE $0.36
  • SST $6.20
  • Average True Range (ATR)
  • VYNE 0.04
  • SST 0.65
  • MACD
  • VYNE -0.02
  • SST -0.06
  • Stochastic Oscillator
  • VYNE 1.79
  • SST 29.95

About VYNE VYNE Therapeutics Inc.

VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.

About SST System1 Inc.

System1 Inc develops technology and data science to operate a responsive acquisition marketing platform. It serves customers in the areas of health and wellness, automotive, finance, travel, and entertainment. The company's segment includes Owned and Operated Advertising (O&O); and Partner Network. It generates maximum revenue from the Owned and Operated Advertising (O&O) segment. Geographically, it operates in United States and Other countries.

Share on Social Networks: